SchizophreniaNewron plans heart tests to lift schizophrenia trial holdItaly’s Newron Pharmaceuticals has disclosed that the FDA kept U.S. enrollment in a Phase 3 trial of its schizophrenia drug evenamide on hold, citing five deaths across all the drug’s clinical studies. … more ➔
AppointmentsAlligator’s CFO takes the top job, Sensorion names finance chief and RQ Bio appoints new CMOEvery Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: a CEO transition shaped by a strategic … more ➔
financingADC Therapeutics buys time for Zynlonta with $86.6M financingSwiss biotech ADC Therapeutics has secured an $86.6 million (€77.5 million) financing agreement alongside debt and royalty deal amendments that extend its expected cash runway into 2029 and remove … more ➔
clinical dataAnother bad day at Zealand: Roche-partnered drug disappoints on blood sugarZealand Pharma shares fell about 4% in Thursday trading after new Phase 2 results for its Roche-partnered obesity drug petrelintide showed encouraging weight loss but a modest improvement in blood sugar … more ➔
licensingRoche taps Chinese biotech Defand in reported $1B dealRoche has partnered with China’s Defand Therapeutics to discover molecular glue degraders for cancer and immune diseases, in a research and licensing agreement reportedly worth close to $1 billion … more ➔
clinical dataArgenx halts Phase 3 Sjögren’s trial, sending shares tumblingArgenx is stopping its Phase 3 UNITY trial of efgartigimod in Sjögren’s disease after an interim analysis showed the study could not meet its primary endpoint. Shares fell about 18% in Euronext Brussels … more ➔
artificial intelligenceRivercell raises $25M to build an AI virtual cellParis-based Rivercell has raised $25 million (about €22 million) in seed funding to generate experimental data and build AI models that predict how human cells respond to drugs and genetic changes … more ➔
SurveyReport: Europe’s biotech leaders see recovery, but investors remain the obstacleExclusive European data from BIO-Europe’s inaugural C-suite survey, shared with European Biotechnology, shows a sector expecting better funding conditions while struggling with investor caution. Among … more ➔
Venture CapitalForbion raises record-breaking €2.3B to back 30 biotechsDutch life sciences investor Forbion has raised €2.3 billion across two new funds to finance about 30 biotech companies, setting a fundraising record for the firm. more ➔
startupSensible secures $47M to rethink mRNA manufacturingOxford-based Sensible Biotechnologies has secured a $47 million (€42 million) financing package to scale a platform that makes mRNA in living cells, targeting manufacturing costs and unwanted immune … more ➔
